Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents)
  4. Volume 22, Issue 4
  5. Article
Volume 22, Issue 4
  • ISSN: 1871-5257
  • E-ISSN: 1875-6182

Abstract

Background

Beta-blockers are essential agents in the management of cardiovascular diseases, such as heart failure, acute myocardial infarction (MI), and cardiac arrhythmias. However, there are diurnal variations in the cardioprotective effects of the subgroups as a result of their different pharmacokinetic, pharmacodynamic, and pharmacogenetic profiles.

Objectives

We aimed to compare metoprolol and bisoprolol in terms of electrocardiogram (ECG) outcomes.

Methods

A retrospective cross-sectional study was conducted at Prince Sultan Cardiac Center. The trial included 404 patients who met the inclusion criteria (204 in the metoprolol arm and 200 in the bisoprolol arm). Using case record forms that had already been created, information, such as patient demographics, medical histories, and treatment histories, was taken from their medical files. The most recent ECG records were also gathered. The ethical approval for this study was obtained from Qassim ethical committee (approval number: 45-44-902).

Results

There was no significant difference found between the patients in both arms in terms of baseline characteristics, age, or sex.

Conclusion

In this retrospective cross-sectional study, we have compared the effects of metoprolol and bisoprolol beta blockers on ECG changes. The findings have indicated no difference between metoprolol and bisoprolol groups in terms of all ECG readings, particularly PR/ms, QTC-ms, and ventricular rate. Further studies are required to confirm these findings.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chamc/10.2174/0118715257252349231018151957
2024-12-01
2024-11-22

  • From This Site

    /content/journals/chamc/10.2174/0118715257252349231018151957
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. JaïsP. CauchemezB. MacleL. DaoudE. KhairyP. SubbiahR. HociniM. ExtramianaF. SacherF. BordacharP. KleinG. WeerasooriyaR. ClémentyJ. HaïssaguerreM. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study.Circulation2008118242498250510.1161/CIRCULATIONAHA.108.772582 19029470
     [Google Scholar]
  2. WongG.W.K. BoydaH.N. WrightJ.M. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension.Cochrane Libr.201620164CD00745110.1002/14651858.CD007451.pub2 26961574
     [Google Scholar]
  3. WongG.W.K. WrightJ.M. Blood pressure lowering efficacy of nonselective beta-blockers for primary hypertension.Cochrane Libr.20142CD00745210.1002/14651858.CD007452.pub2 24585007
     [Google Scholar]
  4. BennettM.T. GulaL.J. KleinG.J. SkanesA.C. YeeR. Leong-SitP. Effect of beta-blockers on QT dynamics in the long QT syndrome: measuring the benefit. Eur Eur pacing, arrhythmias, Card Electrophysiol J Work groups Card pacing, arrhythmias.Card Cell Electrophysiol Eur Soc Cardiol.2014161218471851
     [Google Scholar]
  5. FröhlichH. TorresL. TägerT. SchellbergD. CorlettoA. KazmiS. GoodeK. GrundtvigM. HoleT. KatusH.A. ClelandJ.G.F. AtarD. ClarkA.L. AgewallS. FrankensteinL. Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.Clin. Res. Cardiol.2017106971172110.1007/s00392‑017‑1115‑0 28434020
     [Google Scholar]
  6. EscoubetB. LeclercqJ.F. Maison-BlancheP. PoirierJ.M. GourmelB. Delhotal-LandesB. CoumelP. Comparison of four beta-blockers as assessed by 24-hour ECG recording.Clin. Pharmacol. Ther.198639436136810.1038/clpt.1986.55 3956052
     [Google Scholar]
  7. FDA. LOPRESSOR (metoprolol tartrate) tablet. 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017963s062,018704s021lbl.pdf (accessed on: 2023 Feb 12).
  8. FDA. ZEBETA (bisoprolol fumarate) tablets. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf (accessed on: 2023 Feb 12).
  9. WilkJ.B. MyersR.H. PankowJ.S. HuntS.C. LeppertM.F. FreedmanB.I. ProvinceM.A. EllisonR.C. Adrenergic receptor polymorphisms associated with resting heart rate: the HyperGEN Study.Ann. Hum. Genet.200670556657310.1111/j.1469‑1809.2005.00258.x 16907703
     [Google Scholar]
  10. KongH. LiX. ZhangS. GuoS. NiuW. The β1-adrenoreceptor gene Arg389Gly and Ser49Gly polymorphisms and hypertension: a meta-analysis.Mol. Biol. Rep.20134064047405310.1007/s11033‑012‑2482‑2 23271137
     [Google Scholar]
  11. PacanowskiM.A. GongY. Cooper-DeHoffR.M. SchorkN.J. ShriverM.D. LangaeeT.Y. PepineC.J. JohnsonJ.A. beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension.Clin. Pharmacol. Ther.200884671572110.1038/clpt.2008.139 18615004
     [Google Scholar]
  12. BijlM.J. VisserL.E. van SchaikR.H.N. KorsJ.A. WittemanJ.C.M. HofmanA. VultoA.G. van GelderT. StrickerB.H.C. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.Clin. Pharmacol. Ther.2009851455010.1038/clpt.2008.172 18784654
     [Google Scholar]
  13. DeanL. Thioridazine Therapy and CYP2D6 Genotypes PrattV.M. ScottS.A. PirmohamedM. EsquivelB. KattmanB.L. MalheiroA.J. Bethesda, MD2012
     [Google Scholar]
  14. MelocheM. KhazakaM. KassemI. BarhdadiA. DubéM.P. DenusS. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta‐analysis.Br. J. Clin. Pharmacol.20208661015103310.1111/bcp.14247 32090368
     [Google Scholar]
  15. YangT. JiangY. HaoY. ZhouS. XuX. QuB. LinX. MaT. Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study.Hypertens. Res.2017401798610.1038/hr.2016.101 27534738
     [Google Scholar]
  16. AlHabeebW. MrabetiS. AbdelsalamA.A.I. Therapeutic properties of highly selective β-blockers with or without additional vasodilator properties: focus on bisoprolol and nebivolol in patients with cardiovascular disease.Cardiovasc. Drugs Ther.202236595997110.1007/s10557‑021‑07205‑y 34106365
     [Google Scholar]
  17. JoannidesR. MooreN. IacobM. CompagnonP. LereboursG. MenardJ.F. ThuillezC. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise.Br. J. Clin. Pharmacol.200661212713710.1111/j.1365‑2125.2005.02544.x 16433867
     [Google Scholar]
  18. ChockalingamP. CrottiL. GirardengoG. JohnsonJ.N. HarrisK.M. van der HeijdenJ.F. HauerR.N.W. BeckmannB.M. SpazzoliniC. RordorfR. RydbergA. ClurS.A.B. FischerM. van den HeuvelF. KääbS. BlomN.A. AckermanM.J. SchwartzP.J. WildeA.A.M. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol.J. Am. Coll. Cardiol.201260202092209910.1016/j.jacc.2012.07.046 23083782
     [Google Scholar]
  19. MesquitaE.T. DeusF.C.C. GuedesC.R. MaiaE.R. SubietaC.G.P. VillacortaH. SantosP.A. CramerH. SantosV.B.A. RomeoL.J.M. Effects of propranolol on the QT dispersion in congestive heart failure.Arq. Bras. Cardiol.199973329529810.1590/S0066‑782X1999000900005 10754584
     [Google Scholar]
  20. NozawaT. TaguchiM. TaharaK. HashimotoY. IgarashiN. NonomuraM. KatoB. IgawaA. InoueH. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol.J. Cardiovasc. Pharmacol.200546571372010.1097/01.fjc.0000184117.76188.68 16220080
     [Google Scholar]
  21. LeopoldG. Balanced pharmacokinetics and metabolism of bisoprolol.J. Cardiovasc. Pharmacol.19858Suppl. 11S16S2010.1097/00005344‑198511001‑00003 2439789
     [Google Scholar]
  22. ZisakiA. MiskovicL. HatzimanikatisV. Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches.Curr. Pharm. Des.201421680682210.2174/1381612820666141024151119 25341854
     [Google Scholar]
  23. IngramA. ValenteM. Genetic variation of hepatic enzymes influence on β-blocker dose in patients with reduced ejection fraction heart failure.J. Pharm. Pract.2020331969810.1177/0897190018782794 29916290
     [Google Scholar]
  24. NewtonG.E. ParkerJ.D. Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure.Circulation199694335335810.1161/01.CIR.94.3.353 8759076
     [Google Scholar]
/content/journals/chamc/10.2174/0118715257252349231018151957
Loading
Comparison between the ECG Outcomes of Metoprolol and Bisoprolol
Cardiovasc. Hematol. Agents Med. Chem. 22, 503 (2024); https://doi.org/10.2174/0118715257252349231018151957
/content/journals/chamc/10.2174/0118715257252349231018151957
/content/journals/chamc/10.2174/0118715257252349231018151957
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Beta-blockers; bisoprolol; cardiovascular diseases; ECG; metoprolol; pharmacogenetics

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test